November 20, 2021. A first in human, single ascending dose study to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of AB101 in subjects with type 1 diabetes Read More ».
About Us. ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. Building on nearly two decades of experience and more than 350 metabolic clinical projects conducted, ProSciento provides customized clinical research services for multinational, early